Literature DB >> 16124042

MUC1 and MUC5AC mucin expression in liver fluke-associated intrahepatic cholangiocarcinoma.

Chanchai Boonla1, Banchob Sripa, Peti Thuwajit, Ubon Cha-On, Anucha Puapairoj, Masanao Miwa, Sopit Wongkham.   

Abstract

AIM: To investigate the expressions of MUC1 and MUC5AC in intrahepatic cholangiocarcinoma (ICC). Association of expressions of mucins MUC1 and MUC5AC with clinical findings, metastasis, and survival of the liver fluke-associated ICC patients was determined.
METHODS: The expressions of MUC1 and MUC5AC mucins were examined by immunohistochemical staining in 87 cases of histologically-proven ICC. The expressions of mucins in relationship between clinicopathological significance and prognosis of the patients were evaluated.
RESULTS: Fifty-two patients (60%) exhibited both MUC1 and MUC5AC expressions, whereas 31% expressed either MUC1 or MUC5AC, and 9% expressed neither. High MUC1 immunoreactivity displayed a significant correlation with tumor progression as reflected by vascular invasion (P<0.001), whereas high expression of MUC5AC significantly correlated with neural invasion (P = 0.022) and advanced ICC stage (P = 0.008). Patients with high expression of MUC1 had a significantly shorter survival (P = 0.0002). According to multivariate analyses, MUC1 reactivity (P = 0.026), histological grading and stage of tumor represented the least probability of survival.
CONCLUSION: MUC1 is overexpressed in liver fluke-associated cholangiocarcinoma and relates to vascular invasion and poor prognosis, whereas MUC5AC mucin is neoexpressed and relates to neural invasion and advanced ICC stage. High MUC1 expression in tumor may be useful for predicting the poor outcome of ICC patients.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16124042      PMCID: PMC4321906          DOI: 10.3748/wjg.v11.i32.4939

Source DB:  PubMed          Journal:  World J Gastroenterol        ISSN: 1007-9327            Impact factor:   5.742


  56 in total

1.  Expression of MUC1 mucins in the subserosal layer correlates with postsurgical prognosis of pathological tumor stage 2 carcinoma of the gallbladder.

Authors:  T Kawamoto; J Shoda; T Irimura; N Miyahara; M Furukawa; T Ueda; T Asano; M Kano; N Koike; K Fukao; N Tanaka; T Todoroki
Journal:  Clin Cancer Res       Date:  2001-05       Impact factor: 12.531

2.  Respiratory mucins: identification of core proteins and glycoforms.

Authors:  D J Thornton; I Carlstedt; M Howard; P L Devine; M R Price; J K Sheehan
Journal:  Biochem J       Date:  1996-06-15       Impact factor: 3.857

3.  Macrophage-tumour cell interactions: identification of MUC1 on breast cancer cells as a potential counter-receptor for the macrophage-restricted receptor, sialoadhesin.

Authors:  D Nath; A Hartnell; L Happerfield; D W Miles; J Burchell; J Taylor-Papadimitriou; P R Crocker
Journal:  Immunology       Date:  1999-10       Impact factor: 7.397

4.  Mucin gene expression in biliary epithelial cells.

Authors:  B Vandenhaute; M P Buisine; V Debailleul; B Clément; N Moniaux; M C Dieu; P Degand; N Porchet; J P Aubert
Journal:  J Hepatol       Date:  1997-12       Impact factor: 25.083

5.  Expression of apomucins in the intrahepatic biliary tree in hepatolithiasis differs from that in normal liver and extrahepatic biliary obstruction.

Authors:  M Sasaki; Y Nakanuma; Y S Kim
Journal:  Hepatology       Date:  1998-01       Impact factor: 17.425

6.  Relationships between the synthesis of N-nitrosodimethylamine and immune responses to chronic infection with the carcinogenic parasite, Opisthorchis viverrini, in men.

Authors:  S Satarug; M R Haswell-Elkins; P Sithithaworn; H Bartsch; H Ohshima; M Tsuda; P Mairiang; E Mairiang; P Yongvanit; H Esumi; D B Elkins
Journal:  Carcinogenesis       Date:  1998-03       Impact factor: 4.944

7.  Episialin (MUC1) inhibits cytotoxic lymphocyte-target cell interaction.

Authors:  E van de Wiel-van Kemenade; M J Ligtenberg; A J de Boer; F Buijs; H L Vos; C J Melief; J Hilkens; C G Figdor
Journal:  J Immunol       Date:  1993-07-15       Impact factor: 5.422

8.  MUC1 mucin expression as a marker of progression and metastasis of human colorectal carcinoma.

Authors:  S Nakamori; D M Ota; K R Cleary; K Shirotani; T Irimura
Journal:  Gastroenterology       Date:  1994-02       Impact factor: 22.682

9.  Expression of mucin core protein of mammary type in primary liver cancer.

Authors:  M Sasaki; Y Nakanuma
Journal:  Hepatology       Date:  1994-11       Impact factor: 17.425

10.  Episialin (MUC1) overexpression inhibits integrin-mediated cell adhesion to extracellular matrix components.

Authors:  J Wesseling; S W van der Valk; H L Vos; A Sonnenberg; J Hilkens
Journal:  J Cell Biol       Date:  1995-04       Impact factor: 10.539

View more
  17 in total

Review 1.  Immunotherapeutic Approaches to Biliary Cancer.

Authors:  Urvi A Shah; Amara G Nandikolla; Lakshmi Rajdev
Journal:  Curr Treat Options Oncol       Date:  2017-07

Review 2.  Monitoring outcomes in intrahepatic cholangiocarcinoma patients following hepatic resection.

Authors:  Amir A Rahnemai-Azar; Pallavi Pandey; Ihab Kamel; Timothy M Pawlik
Journal:  Hepat Oncol       Date:  2017-01-20

3.  Long-term survival after resection of mass-forming type intrahepatic cholangiocarcinoma directly infiltrating the transverse colon and sequential brain metastasis: Report of a case.

Authors:  Kenji Mimatsu; Takatsugu Oida; Atsushi Kawasaki; Hisao Kano; Nobutada Fukino; Kazutoshi Kida; Youichi Kuboi; Sadao Amano
Journal:  Surg Today       Date:  2011-09-16       Impact factor: 2.549

4.  Altered expression of MUC2 and MUC5AC in progression of colorectal carcinoma.

Authors:  Xiao-Dong Bu; Nan Li; Xiao-Qiang Tian; Li Li; Jin-Song Wang; Xiao-Jin Yu; Pei-Lin Huang
Journal:  World J Gastroenterol       Date:  2010-08-28       Impact factor: 5.742

5.  New insights on cholangiocarcinoma.

Authors:  Manuela Gatto; Domenico Alvaro
Journal:  World J Gastrointest Oncol       Date:  2010-03-15

Review 6.  Intrahepatic cholangiocarcinoma progression: prognostic factors and basic mechanisms.

Authors:  Alphonse E Sirica; Catherine I Dumur; Deanna J W Campbell; Jorge A Almenara; Olorunseun O Ogunwobi; Jennifer L Dewitt
Journal:  Clin Gastroenterol Hepatol       Date:  2009-11       Impact factor: 11.382

Review 7.  Immunotherapeutic approaches in biliary tract carcinoma: Current status and emerging strategies.

Authors:  Eric I Marks; Nelson S Yee
Journal:  World J Gastrointest Oncol       Date:  2015-11-15

Review 8.  Ramifications of secreted mucin MUC5AC in malignant journey: a holistic view.

Authors:  Shiv Ram Krishn; Koelina Ganguly; Sukhwinder Kaur; Surinder K Batra
Journal:  Carcinogenesis       Date:  2018-05-03       Impact factor: 4.944

9.  Prognostic significance of P27 (Kip 1) and MUC1 in papillary transitional cell carcinoma of the urinary bladder.

Authors:  Taghreed A Abd Elazeez; Abd El-Latef M El-Balshy; Mostafa M Khalil; Magdy M El-Tabye; Hamdy Abdul-Halim
Journal:  Urol Ann       Date:  2011-01

Review 10.  An Omics Perspective on Molecular Biomarkers for Diagnosis, Prognosis, and Therapeutics of Cholangiocarcinoma.

Authors:  Pattaya Seeree; Phorutai Pearngam; Supeecha Kumkate; Tavan Janvilisri
Journal:  Int J Genomics       Date:  2015-09-02       Impact factor: 2.326

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.